Navigation Links
Milwaukee investor gives $10M to business school

Milwaukee Sheldon B. Lubar, who is the founder of Milwaukee investment company Lubar & Co. and has close ties to the University of Wisconsin, is giving $10 million to the business school.

The endowment is the largest the university has received and will fund business professorships, scholarships, and a discretionary fund. Lubar also said he would help the university raise another ......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 02/06/06


Page: 1

Related biology technology :

1. Bruce Maas named CIO at UW-Milwaukee
2. Milwaukee takes another step in electronic patient data exchange
3. Company still behind schedule on Milwaukee wireless project
4. Chicago-Milwaukee "mega-metro" infrastructure improvements are critical
5. Milwaukee software developer gains bottom line, loses waistline
6. Education is fundamental to Milwaukees growth
7. Grow Milwaukee includes millions for tech funding
8. AT&T tech rollout will bring 200 jobs to Milwaukee
9. Bandwidth provider expands in Milwaukee
10. Handicapping Milwaukees wireless initiative
11. Businesses could bridge digital divide in Milwaukee with used computers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Milwaukee investor gives business school

(Date:12/14/2009)... 14 Vermillion, Inc. (Pink Sheets: ... William C. Wallen, Ph.D. Chief Scientific Officer, ... IDEXX Laboratories, will be joining its board ... plan. ,, "Bill brings more than ... diagnostics and biotechnology," said Gail Page, Vermillion ...
(Date:12/14/2009)... Mass., Dec. 14 Boston Scientific Corporation (NYSE: ... a public offering of $2 billion aggregate principal amount ... statement. The public offering consists of $850 million ... of 6.00 percent notes due January 2020 and $300 ... Boston Scientific plans to use the net proceeds for ...
(Date:12/14/2009)... delivery of Brookfield Engineering’s Powder Flow Tester – helping Brookfield ... smaller footprint and more compact design. , ... ... a US-based thermoforming company, has completed the delivery of Brookfield ... metal to a plastic enclosure with a smaller footprint and ...
(Date:12/11/2009)... Therapeutics, Inc., a biopharmaceutical company focused on improving ... cardiovascular and muscle disease, today announced the publication ... crucial role in the progression of amyotrophic lateral ... neuromuscular synaptic regeneration in mice. The findings, ... journal Science , reveal miR-206 as a ...
Breaking Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2
... March 5 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... results for the fourth quarter and year ended December ... results in our Medical Products Business and were able ... initiatives despite a challenging year for TAXUS," said Dr. ...
... appealed, delisting scheduled for March 12, 2009 NEW YORK, ... KERX ) today announced that it received a letter ... that the Company had failed to regain compliance with ... have a minimum of $2,500,000 in stockholders, equity, or ...
... Inc., announced today that it has successfully completed a ... Capital on behalf of the MPM Bio IV NVS ... of a Phase 1/2 human clinical study of its ... disease undergoing surgery for arteriovenous fistula (AVF) creation. Additionally, ...
Other Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 28Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 2Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 3Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 4Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2
(Date:12/11/2009)... , Montreal, December 11, 2009 Canadian ... cancer. In the December 11 edition of the prestigious ... de Montral and the Universit de Sherbrooke explain how ... activity of cytokines, hormones that are culprits in cancer-prone ... people exposed to asbestos. , "Excessive cytokine activity ...
(Date:12/11/2009)... CORVALIS, ORFruit growers, profits have traditionally been ... climates where growing seasons can be short. ... developed varieties are being introduced that offer ... the offseasonresulting in economic bonuses for both ... new varieties of blackberry called "primocane-fruiting", which ...
(Date:12/11/2009)... roe of hake, lumpsucker and salmon is the best dietary ... by researchers at the University of Almera (UAL). The scientists ... found all of these contained high levels of these fatty ... now there had been no precise understanding of the nutritional ... of researchers from the UAL has now shown that this ...
Breaking Biology News(10 mins):Scientists identify natural anti-cancer defenses 2New management methods extend blackberry season 2Roe of marine animals is best natural source of omega-3 2DaVita com Provides Easy Recipes to Plan Your Fathers Day Dinner 49539 1DaVita com Provides Easy Recipes to Plan Your Fathers Day Dinner 49539 2DaVita com Provides Easy Recipes to Plan Your Fathers Day Dinner 49539 3Last Day of Special Olympics Minnesotas 2009 Summer Games 49537 1Last Day of Special Olympics Minnesotas 2009 Summer Games 49537 2Last Day of Special Olympics Minnesotas 2009 Summer Games 49537 3RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 1RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 2RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 3RSA Designated as the Leader in One Time Password Market by Frost 26 Sullivan 8936 4
... reduce age-related macular degeneration ,(AMD) which is the major cause ... the third cause of global blindness, according to,a study published ... , There are two types of AMD, wet and dry. ... loss. A team of researchers across seven European,countries and co-ordinated ...
... in the western U.S., the New Zealand mud snail currently ... into rivers and tributaries, according to a Penn State team ... but are not good fish food replacements for the native ... the shell," says Edward P. Levri, associate professor of biology ...
... Arctic Ocean warms this century, shellfish, snails and other ... of the northern Atlantic that was interrupted by cooling ... of geology at the University of California, Davis, and ... Climate models predict a nearly ice-free Arctic Ocean by ...
Other Biology News:Eat oily fish at least once a week to protect your eyesight in old age 2Tiny invasive snail impacts Great Lakes, alters ecology 2Tiny invasive snail impacts Great Lakes, alters ecology 3Pacific shellfish ready to invade Atlantic 2
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
Inquire...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Biology Products: